Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It?

Clin Drug Investig. 2023 May;43(5):365-367. doi: 10.1007/s40261-023-01271-w. Epub 2023 May 8.

Authors

Luigi Gargiulo^{1

2}, Luciano Ibba^{3

4}, Andrea Cortese^{1

2}, Angela Alfano^{1

2}, Mario Valenti^{1

2}, Antonio Costanzo^{1

2}, Alessandra Narcisi¹

Affiliations

¹ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
² Department of Biomedical Sciences, Humanitas University, 20090, Pieve Emanuele, MI, Italy.
³ Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy. [email protected].
⁴ Department of Biomedical Sciences, Humanitas University, 20090, Pieve Emanuele, MI, Italy. [email protected].

PMID: 37155117
DOI: 10.1007/s40261-023-01271-w

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Humans
Interleukin Inhibitors*
Interleukin-23
Psoriasis* / drug therapy

Substances

Interleukin Inhibitors
Antibodies, Monoclonal
Interleukin-23